Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.

Cost-effectiveness acceptability curves (CEACs) have been widely adopted as a method to quantify and graphically represent uncertainty in economic evaluation studies of health-care technologies. However, there remain some common fallacies regarding the nature and shape of CEACs that largely result from the 'textbook' illustration of the CEAC. This 'textbook' CEAC shows a smooth curve starting at probability 0, with an asymptote to 1 for higher money values of the health outcome (lambda). But this familiar 'ogive' shape which makes the 'textbook' CEAC look like a cumulative distribution function is just one special case of the CEAC. The reality is that the CEAC can take many shapes and turns because it is a graphic transformation from the cost-effectiveness plane, where the joint density of incremental costs and effects may 'straddle' quadrants with attendant discontinuities and asymptotes. In fact CEACs: (i) do not have to cut the y-axis at 0; (ii) do not have to asymptote to 1; (iii) are not always monotonically increasing in lambda; and (iv) do not represent cumulative distribution functions (cdfs). Within this paper we present a 'gallery' of CEACs in order to identify the fallacies and illustrate the facts surrounding the CEAC. The aim of the paper is to serve as a reference tool to accompany the increased use of CEACs within major medical journals.

[1]  Mark Sculpher,et al.  Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling , 2000 .

[2]  K Claxton,et al.  Redefining the analytical approach to pharmacoeconomics. , 1999, Health economics.

[3]  P. Bower,et al.  Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses , 2003, BMJ : British Medical Journal.

[4]  Andrew Briggs,et al.  Cost-effectiveness and cost-utility of long-term management strategies for heartburn. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  W C Black,et al.  The CE Plane , 1990, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[7]  Anthony O'Hagan,et al.  The probability of cost-effectiveness , 2002, BMC medical research methodology.

[8]  A Briggs,et al.  Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, Health economics.

[9]  M Gent,et al.  Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: The Canadian Implantable Defibrillator Study , 2001, Circulation.

[10]  A H Briggs,et al.  A Bayesian approach to stochastic cost-effectiveness analysis. , 1999, Health economics.

[11]  M. Drummond,et al.  An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. , 2003, Chest.

[12]  B J O'Brien,et al.  Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods , 2002, Statistical methods in medical research.

[13]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[14]  Paul Fenn,et al.  Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) , 2000, BMJ : British Medical Journal.

[15]  Philip D. Harvey,et al.  Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 , 1998, BMJ.

[16]  N. Zethraeus,et al.  On the interpretation of cost-effectiveness acceptability curves , 2000 .

[17]  A COST-EFFECTIVENESS ANALYSIS OF rhDNase IN CHILDREN WITH CYSTIC FIBROSIS , 2003, International Journal of Technology Assessment in Health Care.

[18]  M. Dewey,et al.  COUNSELING VERSUS ANTIDEPRESSANT THERAPY FOR THE TREATMENT OF MILD TO MODERATE DEPRESSION IN PRIMARY CARE , 2003, International Journal of Technology Assessment in Health Care.

[19]  Ruth Etzioni,et al.  Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. , 2003, The New England journal of medicine.

[20]  A J Moskowitz,et al.  Bayesian estimation of cost-effectiveness ratios from clinical trials. , 1999, Health economics.

[21]  A H Briggs,et al.  Handling uncertainty when performing economic evaluation of healthcare interventions. , 1999, Health technology assessment.

[22]  B. Delaney,et al.  Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care , 2000, The Lancet.

[23]  P A Poole-Wilson,et al.  Low doses vs. high doses of the angiotensin converting‐enzyme inhibitor lisinopril in chronic heart failure: a cost‐effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study , 2000, European journal of heart failure.

[24]  M. Drummond,et al.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.

[25]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[26]  Anthony O'Hagan,et al.  Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. , 2003, BMJ : British Medical Journal.

[27]  O C Ukoumunne,et al.  Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach , 2003, Psychological Medicine.

[28]  S. Gabriel,et al.  The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[29]  N. Zethraeus,et al.  Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.